457 related articles for article (PubMed ID: 32209637)
1. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
[TBL] [Abstract][Full Text] [Related]
2. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.
Ferrari de Andrade L; Tay RE; Pan D; Luoma AM; Ito Y; Badrinath S; Tsoucas D; Franz B; May KF; Harvey CJ; Kobold S; Pyrdol JW; Yoon C; Yuan GC; Hodi FS; Dranoff G; Wucherpfennig KW
Science; 2018 Mar; 359(6383):1537-1542. PubMed ID: 29599246
[TBL] [Abstract][Full Text] [Related]
3. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
4. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
5. Sulforaphane induces ROS mediated induction of NKG2D ligands in human cancer cell lines and enhances susceptibility to NK cell mediated lysis.
Amin PJ; Shankar BS
Life Sci; 2015 Apr; 126():19-27. PubMed ID: 25721293
[TBL] [Abstract][Full Text] [Related]
6. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
7. MICA/IL-12: A novel bifunctional protein for killer cell activation.
Tietje A; Yang X; Yu X; Wei Y
Oncol Rep; 2017 Mar; 37(3):1889-1895. PubMed ID: 28098874
[TBL] [Abstract][Full Text] [Related]
8. A novel MICA/B-targeted chimeric antigen receptor augments the cytotoxicity of NK cells against tumor cells.
Guo C; Dong M; Wang X; Yu J; Jin X; Cheng S; Cui F; Qian Y; Bao Q; Zhi L; Niu Z; Li M; Zhu W
Biochem Biophys Res Commun; 2024 May; 710():149918. PubMed ID: 38598902
[TBL] [Abstract][Full Text] [Related]
9. NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells.
Schilling D; Kühnel A; Tetzlaff F; Konrad S; Multhoff G
Cancer Immunol Immunother; 2015 May; 64(5):599-608. PubMed ID: 25854583
[TBL] [Abstract][Full Text] [Related]
10. Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity.
Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Nishioka T; Fukunaga S; Futani H; Okamura H; Terada N
Oncol Rep; 2010 Dec; 24(6):1621-7. PubMed ID: 21042760
[TBL] [Abstract][Full Text] [Related]
11. Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.
Carreno BM; Garbow JR; Kolar GR; Jackson EN; Engelbach JA; Becker-Hapak M; Carayannopoulos LN; Piwnica-Worms D; Linette GP
Clin Cancer Res; 2009 May; 15(10):3277-86. PubMed ID: 19447870
[TBL] [Abstract][Full Text] [Related]
12. Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein.
Torres N; Regge MV; Secchiari F; Friedrich AD; Spallanzani RG; Raffo Iraolagoitia XL; Núñez SY; Sierra JM; Ziblat A; Santilli MC; Gilio N; Almada E; Lauche C; Pardo R; Domaica CI; Fuertes MB; Madauss KP; Hance KW; Gloger IS; Zylberman V; Goldbaum FA; Zwirner NW
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32518090
[TBL] [Abstract][Full Text] [Related]
13. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity.
Fuertes MB; Girart MV; Molinero LL; Domaica CI; Rossi LE; Barrio MM; Mordoh J; Rabinovich GA; Zwirner NW
J Immunol; 2008 Apr; 180(7):4606-14. PubMed ID: 18354183
[TBL] [Abstract][Full Text] [Related]
14. MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner.
Du C; Bevers J; Cook R; Lombana TN; Rajasekaran K; Matsumoto M; Spiess C; Kim JM; Ye Z
J Immunother Cancer; 2019 Aug; 7(1):207. PubMed ID: 31387641
[TBL] [Abstract][Full Text] [Related]
15. MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
Kim Y; Born C; Bléry M; Steinle A
Front Immunol; 2020; 11():960. PubMed ID: 32582150
[TBL] [Abstract][Full Text] [Related]
16. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.
Bilotta MT; Abruzzese MP; Molfetta R; Scarno G; Fionda C; Zingoni A; Soriani A; Garofalo T; Petrucci MT; Ricciardi MR; Paolini R; Santoni A; Cippitelli M
FASEB J; 2019 Aug; 33(8):9489-9504. PubMed ID: 31125275
[TBL] [Abstract][Full Text] [Related]
17. The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands.
Elsner L; Muppala V; Gehrmann M; Lozano J; Malzahn D; Bickeböller H; Brunner E; Zientkowska M; Herrmann T; Walter L; Alves F; Multhoff G; Dressel R
J Immunol; 2007 Oct; 179(8):5523-33. PubMed ID: 17911639
[TBL] [Abstract][Full Text] [Related]
18. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
Mei JZ; Guo KY; Wei HM; Song CY
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
[TBL] [Abstract][Full Text] [Related]
19. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
20. Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding.
Agüera-González S; Gross CC; Fernández-Messina L; Ashiru O; Esteso G; Hang HC; Reyburn HT; Long EO; Valés-Gómez M
Eur J Immunol; 2011 Dec; 41(12):3667-76. PubMed ID: 21928280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]